
CLAIMS

1. Use of a compound of the general formula **(I)**




(I)


wherein the single elements T or P are connected in either direction from the carbonyl (C=O) point of attachment to the nitrogen (N) of the next element and wherein

– either


T^1 is an α-amino acid residue of one of the formulae




AA1




AA2




AA3




AA4




AA5




AA6




AA7



AA8




AA9




AA10

and


T^2 is an α-amino acid residue of one of the formulae




AA11




AA12




AA13




AA14



AA15




AA16




AA17

– or


T^1 is an α-amino acid residue of one of the formulae




AA18




AA19




AA20



AA21




AA22




AA23

and


T^2 is an α-amino acid residue of one of the formulae AA11 to AA17, hereinabove, or an α-amino acid residue of one of the formulae




AA24




AA25




AA26




AA27




AA28




AA29



AA30



AA31




AA32


P^1, P^3 and P^4 are independently

~~$-NR^1CH(R^{29})CO-$; $-NR^1CH(R^{30})CO-$; or $-NR^1CH(R^{31})CO-$;~~

P^2 is an α-amino acid residue of one of the formulae



AA33



AA34

A is O; NR^{17}; S; SO; or SO_2;

X is OH; NH_2; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

Y is NH_2; F; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

R^1, R^2 and R^3 are independently

H; CF_3; lower alkyl; lower alkenyl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R^4, R^5, R^6, R^7 and R^8 are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_nO(CHR^2)_mR^{35}$; or

R^4 and R^2 taken together can form

=O; $-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5; R^5 and R^6; R^6 and R^7; R^7 and R^8; or R^6 and R^9 taken together can form:

$-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5 are independently X;

R^9, R^{10}, R^{11} and R^{12} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_rOR^{17}$; $-(CHR^{15})_rSR^{17}$; $-(CHR^{15})_rNR^{17}R^{18}$; $-(CHR^{15})_rOCONR^{17}R^{18}$; $-(CHR^{15})_rNR^1CONR^{17}R^{18}$; $-(CHR^{15})_rNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_rPO(OR^1)_2$; $-(CHR^{15})_rSO_2R^{17}$; $-(CHR^{15})_rNR^1SO_2R^{17}$; $-(CHR^{15})_rSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or

$-(CHR^1)_rO(CHR^1)_oR^{35}$; or

R^{11} and R^{12} taken together can form

=O; or $=NR^1$;

R^{13} and R^{14} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_rO(CHR^1)_oR^{35}$;

R^{15} is H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^{17}R^{18}$; $-(CHR^1)_oNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; $-(CHR^1)_oSO_2R^{17}$; or $-(CHR^1)_oSO_2NR^{17}R^{18}$;

R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; heteroaryl-heterocycloalkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;


R^{17}, R^{18}, R^{19} and R^{20} are independently

H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; or heteroaryl-heterocycloalkyl; or


the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form:

heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl;


or a group of one of the formulae




C1




C2




C3




C4




C5



C6



C7



C8

Z, Z' and Z'' are independently

$-CR^{39}$; or N;

R^{21}, R^{22}, R^{23} and R^{24} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_nO(CHR^2)_mR^{38}$;

R^{25} and R^{26} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_rOR^{17}$; $-(CHR^1)_rSR^{17}$; $-(CHR^1)_rNR^2R^{17}$; $-(CHR^1)_rOCONR^2R^{17}$; $-(CHR^1)_rNR^2CONR^3R^{17}$;$-(CHR^1)_rNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_rPO(OR^2)_2$; $-(CHR^1)_rSO_2R^{17}$; $-(CHR^1)_rNR^2SO_2R^{17}$; $-(CHR^1)_rSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{27} is H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{29} is H; alkyl; alkenyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; $-(CHR^4)_oOR^{17}$; $-(CHR^4)_oSR^{17}$; or $-(CHR^4)_rNR^{17}R^{18}$;

R^{30} is $-(CR^1R^4)_nR^{35}$; $-(CH_2)_nO(CH_2)_mR^{35}$; $-(CH_2)_nS(CH_2)_mR^{35}$; or $-(CH_2)_nNR^1(CH_2)_mR^{35}$;


R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}R^{32}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qOR^{32}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{19}SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^2)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

R^{32} is $-COR^{29}$; $-COR^{30}$; $-CO(CR^1R^{15})_oR^{17}$; $-CO(CR^1R^{15})_oOR^{17}$; $-CO(CR^1R^{15})_oNR^{17}R^{18}$; $-CO(CR^1R^{15})_oNR^2R^{16}$; $-CO(CR^1R^{29})NR^{17}R^{18}$; $-CO(CR^1R^{30})NR^{17}R^{18}$; $-CO(CR^1R^{34})NR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}SO_2R^{18}$; $-CO(CR^1R^{15})_oNR^{17}SO_2R^{18}$; $-CONR^1(CHR^{17})_nNR^2(CHR^{15})_mR^{16}$; $-CO(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-CONR^1(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-SO_2R^{29}$; $-SO_2R^{30}$; $-SO_2(CR^1R^{15})_oR^{17}$; or $-SO_2(CR^1R^{15})_oNR^{17}R^{18}$;


R^{33} is $-NR^1C(R^2)(R^{29})COOR^{17}$; $-NR^1C(R^2)(R^{29})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{30})COOR^{17}$; $-NR^1C(R^2)(R^{30})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{34})COOR^{17}$; or $-NR^1C(R^2)(R^{34})CONR^{17}R^{18}$;

R^{34} is $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CH_2)_qC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$;
$-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^2C(=NR^{19})NR^{17}R^{18}$;
$-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$;
$-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^1R^{16}$;
$-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^1)_2$;
$-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$;
$-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$;
$-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$;
$-(CR^1R^{15})_qCOOR^{17}$; or $-(CR^1R^{15})_qCONR^{17}R^{18}$;


R^{35} is an aryl group of one of the formulae



AR1




AR2




AR3


or a heteroaryl group of one of the formulae




H1




H2




H3




H4




H5




H6




H7




H8




H9




H10




H11




H12




H13





H14





H15



H16
H17
H18
H19
H20
H21
H22
H23
H24
H25
H26
H27
H28
H29
H30
H31
H32
H33
H34
H35
H36
H37
H38
H39
H40
H41
H42
H43
H44



H45



H46


H47


H48


H49


H50


H51

R^{36} and R^{37} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_oR^{38}$; $-(CH_2)_oOR^{17}$; $-O(CH_2)_oR^{38}$; $-(CH_2)_oSR^{17}$; $-(CH_2)_oNR^{17}R^{18}$; $-(CH_2)_oOCONR^{17}R^{18}$; $-(CH_2)_oNR^1CONR^{17}R^{18}$; $-(CH_2)_oNR^1COR^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^{17}R^{18}$; $-(CH_2)_oPO(OR^1)_2$; $-(CH_2)_oSO_2R^{16}$; or $-(CH_2)_oCOR^{17}$;

R^{38} is an aryl group of the formula


AR4

R^{39}, R^{40} and R^{41} are independently

H; F; Cl; Br; OH; NH_2; NO_2; CN; CF_3; $OCHF_2$; OCF_3; $-NR^1R^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^1R^{17}$; lower alkyl; lower alkoxy; or lower alkenyl;

R^{42} is H; lower alkyl; or aryl-lower alkyl;

n and m are independently an integer of 0-5 with the proviso that $n+m \leq 6$;

o is 0-4; p is 2-6; q is 1-6; r is 1-3; s is 0-4;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition related to the activity of CXCR7.

2. The use according to claim 1 wherein

R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form: heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl; or a group of one of the above formulae C1 to C8;

R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

s is 2-4.

3. The use according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

~~then T^2 can in addition be~~

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1, P^3 and P^4 are independently

Ala; Arg; Asn; Asp; Cit; Cys; Glu; Gln; Gly; His; Ile; Leu; Lys; Met; Orn; Phe; Pro; Ser; Thr; Trp; Tyr; Val; Abu; Agb; Agp; Ala(*t*Bu); Ala(*c*Pr); Ala(2Furyl); Ala(3Furyl); Ala(Ppz); Ala(1Pyraz); Ala(2Quin); Ala(3Quin); Ala(4Quin); Ala(Tet); Azt; Bbta; Bip; Cha; Chg; Dab; Dab(Ac); Dab(*c*Pr); Dab(*i*Pr); Dab($4Me_2NPhSO_2$); Dab(MeOEtNCO); Dab(MePpzCO); Dab($MeSO_2$); Dab(morphCO); Dab(1Nal); Dab(2Nal); Dap; Dap($CONH_2$); Dap(MeOEt); Dap($(MeOEt)_2$); Deg; Gly(*t*Bu); hArg; hCha; hCys; hHis; hLys; hPhe; hSer; hSer(Me); hTrp; hTyr; His(Me); His(Bn); Hyp(Bn); (4*S*)-Hyp(Bn); Hyp(4BrBn); Hyp(3CNBn); Hyp(4CNBn); Hyp(CONHPh); Hyp(Ph); Lys(Ac); Lys(Bz); Lys(*c*Pr); Lys(*i*Pr); Lys(Me); Lys(Nic); Lys((5*R*)OH); Lys(4Oxa); Met(O_2); 1Nal; 2Nal; Nle; Nle(6OBn); OctG; Oic; Orn(*c*Pr); Orn(*i*Pr); 2Pal; 3Pal; 4Pal; Phe(2Cl); Phe(3Cl); Phe(4Cl); Phe($3,4Cl_2$); Phe(2F); Phe(3F); Phe(4F); Phe(4CN); Phe($4CF_3$); Phe(4COOMe); Phg; Pip; Pro((4*R*)Bn); Pro((4*S*)F); Pro((4*S*)*c*Hex); Pro($5,5Me_2$); Ser(Bn); Ser(Me); Thi; *allo*Thr; Thr(Bn); Thz; Thz($5,5Me_2$); Tic; Tic(7OH); Trp(7Aza); Trp(5Br); Trp(6Br); Trp($6CF_3$); Trp(5Cl); Trp(6Cl); Trp(5,6Cl); Trp(5OH); Tyr(Bn); Tyr(Me); Tyr(4MeOCOBn); Tyr(Ph); Tyr(4OHPh); Tza; Gln(Alk1); Gln(Alk2); Gln(Alk3); Gln(Alk4); Gln(Alk5); Gln(Alk6); Gln(Alk7); Gln(Alk8); Gln(Alk9); Gln(Alk10); Gln(Alk11); Gln(Alk12); Gln(Alk13); Gln(Alk14); Gln(Alk15); Gln(Alk16); Gln(Alk17); Gln(Alk18); Gln(Alk19); Gln(Alk20); Gln(Alk21); Gln(Alk22); Gln(Alk23); Gln(Alk24); Gln(Alk25); Gln(Alk26); Gln(Alk27); Gln(Alk28); Gln(Alk29); Gln(Alk30); Gln(Alk31); Gln(Alk32); Gln(Alk33); Gln(Alk34); Glu(cN1); Glu(cN2); Glu(cN3); Glu(cN4); Glu(cN5); Glu(cN6); Glu(cN7); Glu(cN8); Glu(cN9); Glu(cN10); Glu(cN11); Glu(cN12); Glu(cN13); Glu(cN14); Glu(cN15); Glu(cN16); Glu(cN17); Lys(Ar1); Lys(Ar2); Lys(Ar3); Lys(Ar4); Lys(Ar5); Lys(Ar6); Lys(Ar7); Lys(Ar8); Lys(Ar9); Lys(Ar10); Lys(Ar11); Lys(Ar12); Orn(Ar1); Orn(Ar2); Orn(Ar3); Orn(Ar4); Orn(Ar5); Orn(Ar6); Orn(Ar7); Orn(Ar8); Orn(Ar9); Orn(Ar10); Orn(Ar11);

Orn(Ar12); Dab(Ar1); Dab(Ar2); Dab(Ar3); Dab(Ar4); Dab(Ar5); Dab(Ar6); Dab(Ar7); Dab(Ar8); Dab(Ar9); Dab(Ar10); Dab(Ar11); Dab(Ar12); Dab(S1); Dab(S2); Dab(S3); Dab(S4); Dab(S5); Dab(S6); Dab(S7); Dab(S8); Dab(S9); Dab(S10); Dab(S11); Dab(S12); Dab(S13); Dab(S14); Dab(S15); Dab(S16); Dab(S17); Dab(S18); Dab(A1); Dab(A2); Dab(A3); Dab(A4); Dab(A5); Dab(A6); Dab(A7); Dab(A8); Dab(A9); Dab(A10); Dab(A11); Dab(A12); Dab(A13); Dab(A14); Dab(A15); Dab(A16); Dab(A17); Dab(A18); Dab(A19); Dab(A20); Dab(A21); Dab(A22); Dab(A23); Dab(A24); Dab(A25); Dab(A26); Dab(A27); Dab(A28); Dab(A29); Dab(A30); Dab(A31); Dab(A32); Dab(A33); Dab(A34); Dab(A35); Dab(A36); Dab(A37); Dab(A38); Dab(A39); Dab(A40); Dab(A41); Dab(A42); Dab(A43); Dab(A44); Dab(A45); Dab(A46); Dab(A47); Dab(A48); Dab(A49); Dab(A50); Dab(A51); Dab(A52); Dab(A53); Dab(A54); Dab(A55); Orn(A1); Orn(A2); Orn(A3); Orn(A4); Orn(A5); Orn(A6); Orn(A7); Orn(A8); Orn(A9); Orn(A10); Orn(A11); Orn(A12); Orn(A13); Orn(A14); Orn(A15); Orn(A16); Orn(A17); Orn(A18); Orn(A19); Orn(A20); Orn(A21); Orn(A22); Orn(A23); Orn(A24); Orn(A25); Orn(A26); Orn(A27); Orn(A28); Orn(A29); Orn(A30); Orn(A31); Orn(A32); Orn(A33); Orn(A34); Orn(A35); Orn(A36); Orn(A37); Orn(A38); Orn(A39); Orn(A40); Orn(A41); Orn(A42); Orn(A43); Orn(A44); Orn(A45); Orn(A46); Orn(A47); Orn(A48); Orn(A49); Orn(A50); Orn(A51); Orn(A52); Orn(A53); Orn(A54); Orn(A55); Orn(A56); Asn(Alk1); Asn(Alk2); Asn(Alk3); Asn(Alk4); Asn(Alk5); Asn(Alk6); Asn(Alk7); Asn(Alk8); Asn(Alk9); Asn(Alk10); Asn(Alk11); Asn(Alk12); Asn(Alk13); Asn(Alk14); Asn(Alk15); Asn(Alk16); Asn(Alk17); Asn(Alk18); Asn(Alk19); Asn(Alk20); Asn(Alk21); Asn(Alk22); Asn(Alk23); Asn(Alk24); Asn(Alk25); Asn(Alk26); Asn(Alk27); Asn(Alk28); Asn(Alk29); Asn(Alk30); Asn(Alk31); Asn(Alk32); Asn(Alk33); Asn(Alk34); Asp(cN1); Asp(cN2); Asp(cN3); Asp(cN4); Asp(cN5); Asp(cN6); Asp(cN7); Asp(cN8); Asp(cN9); Asp(cN10); Asp(cN11); Asp(cN12); Asp(cN13); Asp(cN14); Asp(cN15); Asp(cN16); Asp(cN17); Dap(Ar1); Dap(Ar2); Dap(Ar3); Dap(Ar4); Dap(Ar5); Dap(Ar6); Dap(Ar7); Dap(Ar8); Dap(Ar9); Dap(Ar10); Dap(Ar11); Dap(Ar12); Dap(S1); Dap(S2); Dap(S3); Dap(S4); Dap(S5);

~~Dap(S6); Dap(S7); Dap(S8); Dap(S9); Dap(S10); Dap(S11); Dap(S12); Dap(S13);~~ Dap(S14); Dap(S15); Dap(S16); Dap(S17); Dap(S18); Dap(A1); Dap(A2); Dap(A3); Dap(A4); Dap(A5); Dap(A6); Dap(A7); Dap(A8); Dap(A9); Dap(A10); Dap(A11); Dap(A12); Dap(A13); Dap(A14); Dap(A15); Dap(A16); Dap(A17); Dap(A18); Dap(A19); Dap(A20); Dap(A21); Dap(A22); Dap(A23); Dap(A24); Dap(A25); Dap(A26); Dap(A27); Dap(A28); Dap(A29); Dap(A30); Dap(A31); Dap(A32); Dap(A33); Dap(A34); Dap(A35); Dap(A36); Dap(A37); Dap(A38); Dap(A39); Dap(A40); Dap(A41); Dap(A42); Dap(A43); Dap(A44); Dap(A45); Dap(A46); Dap(A47); Dap(A48); Dap(A49); Dap(A50); Dap(A51); Dap(A52); Dap(A53); Dap(A54); or Dap(A55);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dab; ^{D}Phe; ^{D}Phe(4CF_3); ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; ^{D}4Pal; ^{D}Lys(Ar1); ^{D}Lys(Ar2); ^{D}Lys(Ar3); ^{D}Lys(Ar4); ^{D}Lys(Ar5); ^{D}Lys(Ar6); ^{D}Lys(Ar7); ^{D}Lys(Ar8); ^{D}Lys(Ar9); ^{D}Lys(Ar10); ^{D}Lys(Ar11); ^{D}Lys(Ar12); ^{D}Orn(A41); ^{D}Orn(A56); ^{D}Orn(Ar1); ^{D}Orn(Ar2); ^{D}Orn(Ar3); ^{D}Orn(Ar4); ^{D}Orn(Ar5); ^{D}Orn(Ar6); ^{D}Orn(Ar7); ^{D}Orn(Ar8); ^{D}Orn(Ar9); ^{D}Orn(Ar10); ^{D}Orn(Ar11); ^{D}Orn(Ar12); ^{D}Dab(Ar1); ^{D}Dab(Ar2); ^{D}Dab(Ar3); ^{D}Dab(Ar4); ^{D}Dab(Ar5); ^{D}Dab(Ar6); ^{D}Dab(Ar7); ^{D}Dab(Ar8); ^{D}Dab(Ar9); ^{D}Dab(Ar10); ^{D}Dab(Ar11); ^{D}Dab(Ar12); ^{D}Dap(Ar1); ^{D}Dap(Ar2); ^{D}Dap(Ar3); ^{D}Dap(Ar4); ^{D}Dap(Ar5); ^{D}Dap(Ar6); ^{D}Dap(Ar7); ^{D}Dap(Ar8); ^{D}Dap(Ar9); ^{D}Dap(Ar10); ^{D}Dap(Ar11); or ^{D}Dap(Ar12).

4. The use according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); ~~Pro((4*S*)NHBz); or Mor; or~~

~~when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2);~~ ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Ala(*c*Pr); Ala(1Pyraz); Ala(Tet); Trp; 1Nal; 2Nal; Phe; Tyr; 2Pal; 3Pal; 4Pal; Thr; His; Arg; hArg; Agb; Pip; Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dap; ^{D}Phe; ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; or ^{D}4Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Cit; Thr; Dab; Dap; Phe; Trp; His; Tyr; or Ile

P^4 is Trp; His; Phe; Phe(4CF_3); 1Nal; 2Nal; Tyr; Leu; Ile; Arg; hArg; Lys; Dab; Dap; Orn; Orn(A56); or Orn(Ar7).

5. The use according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); or ^{D}Pro((4*S*)NH_2);

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*S*)OH); (4*S*)-Hyp(Bn); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Trp; 1Nal; Tyr; 3Pal; Thr; His; Arg; hArg; Agb; Pip; Ala(1Pyraz); Ala(Tet); Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Phe; ^{D}Trp; ^{D}His; or ^{D}3Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Dab; Trp; or His;

P^4 is Trp; His; Phe; Phe(4CF_3); 1Nal; 2Nal; Tyr; Ile; Arg; hArg; Lys; Dab; Orn; Orn(A56); or Orn(Ar7).

6. The use according claim 1, wherein the compound of formula **(I)** is selected from

cyclo(-Ile-^{D}Arg-Arg-Ile-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Tyr-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Lys-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Dab-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Dab-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Thr-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-hSer-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-*allo*Thr-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Lys-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}His-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Cit-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-1Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Thr-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Ile-^{D}Arg-Agp-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Agb-Trp-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Tyr-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Lys-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-His-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Pip-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-hArg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Agb-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}3Pal-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-hArg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)F)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*R*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Mor-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Mor-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-(4*S*)-Hyp(Bn)-);

cyclo(-His-^{D}Trp-His-Trp-^{D}Pro- Pro((4*S*)NHBz)-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*S*)OH)-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*R*)NH_2)-Thr-);

cyclo(-Val-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Abu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Leu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Nle-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Cha-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Orn-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A41)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Tic-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3S)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(A56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

7. The use according claim 6, wherein the compound of formula **(I)** is selected from

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

and pharmaceutically acceptable salts thereof.

8. The use according claim 6, wherein the compound of formula **(I)** is selected from

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

9. The use according to any one of claims 1 to 8, wherein the compound of formula **(I)** is an epimer or a diastereomer based on one or more chiral centers not explicitly specified in formula **(I)**.

10. The use of a compound of formula **(I)** as defined in any one of claims 1 to 9 in the manufacture of a medicament for the treatment of a disease or condition treatable by modulating activity against the CXCR7 receptor.

11. The use according to claim 10, wherein the disease or condition is treatable by interfering selectively with the natural activity of the CXCR7 receptor and its natural ligands CXCL11 and/or CXCL12.

12. The use of a compound of formula **(I)** as defined in any one of claims 1 to 9 for the manufacture of a medicament for the treatment, prevention or the supportive treatment of a disease or condition related to the activity of CXCR7 selected from dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and oncology, or the mobilisation of stem cells.

13. The use according to claim 12, wherein the wherein the disease or condition related to the activity of CXCR7 is selected from HIV infections, Epstein-Barr Virus infection; Type I and/or Type II diabetes mellitus; conjunctivitis, scleritis, uveitis, rhinosinusitis, Whim syndrome, lupus erythematosus, osteoarthritis, rheumatoid arthritis, synovitis, psoriasis, multiple sclerosis, Crohns disease, inflammatory bowel disease, mixed connective tissue disease, chronic lymphocytic thyroiditis, Graves' disease, graft-versus-host disease, Sjögren's syndrome; dry eye syndrome, glaucoma, age-related macular degeneration; pulmonary arterial hypertension, pulmonary hypoxia, atherosclerosis, myocarditis, heart failure including myocardial infarction, arterial thrombosis, stroke and angiogenesis; chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma; sarcomaincluding osteosarcoma, rhabdomyosarcoma, Kaposi's sarcoma and synovial sarcoma; lipoma including angiolipoma; glioblastoma multiforme, astrocytomas, neuroblastoma; carcinoma

~~including adenocarcinoma; malignant epithelial and mucoepidermoid neoplasms,~~ thyroid neoplasm, gonadal neoplasms, prostate cancer, breast cancer, melanoma, lung carcinoma, pancreatic carcinoma, colorectal cancer; solid tumors; lymphoma including Birkitt's lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma; multiple myeloma and leukemia; and metastasis.

14. Use of a compound of formula **(I)** as defined in any one of claims 1 to 9, in the manufacture of a medicament for the inhibition of neointima formation; stem cell mobilisation of peripheral blood stem cells and/or mesenchymal stem cells; mobilisation of endothelial or neuronal progenitor cells; or tissue-repair in human or other mammals.


15. The use according to any one of claims 1 to 14, wherein the medicament is in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation administration.

16. The use according to claim 15, wherein the medicament is in the form of a tablet, a dragee, a capsule, a solution, a liquid, a gel, a plaster, a cream, an ointment, a syrup, a slurry, a suspension, a spray, a nebuliser or a suppository.

17. The use according to any one of claims 1 to 16, wherein the medicament is adapted to administer the compound of formula (I) as the sole active pharmaceutical ingredient or in combination with one or more other active pharmaceutical ingredients ~~present in the medicament or in another medicament.~~

CLAIMS

1. Use of a compound of the general formula **(I)**




(I)


wherein the single elements T or P are connected in either direction from the carbonyl (C=O) point of attachment to the nitrogen (N) of the next element and wherein

– either


T^1 is an α-amino acid residue of one of the formulae




AA1




AA2




AA3




AA4




AA5




AA6




AA7



AA8




AA9




AA10

and


T^2 is an α-amino acid residue of one of the formulae




AA11




AA12




AA13




AA14



AA15




AA16




AA17

– or


T^1 is an α-amino acid residue of one of the formulae




AA18




AA19




AA20



AA21




AA22




AA23

and


T^2 is an α-amino acid residue of one of the formulae AA11 to AA17, hereinabove, or ar α-amino acid residue of one of the formulae




AA24




AA25




AA26




AA27




AA28




AA29



AA30



AA31




AA32

P^1, P^3 and P^4 are independently

$-NR^1CH(R^{29})CO-$; $-NR^1CH(R^{30})CO-$; or $-NR^1CH(R^{31})CO-$;

P^2 is an α-amino acid residue of one of the formulae



AA33 AA34

A is O; NR^{17}; S; SO; or SO_2;

X is OH; NH_2; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

Y is NH_2; F; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

R^1, R^2 and R^3 are independently

H; CF_3; lower alkyl; lower alkenyl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R^4, R^5, R^6, R^7 and R^8 are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_nO(CHR^2)_mR^{35}$; or

R^4 and R^2 taken together can form

=O; $-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5; R^5 and R^6; R^6 and R^7; R^7 and R^8; or R^6 and R^9 taken together can form:

$-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5 are independently X;

R^9, R^{10}, R^{11} and R^{12} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_rOR^{17}$; $-(CHR^{15})_rSR^{17}$; $-(CHR^{15})_rNR^{17}R^{18}$; $-(CHR^{15})_rOCONR^{17}R^{18}$; $-(CHR^{15})_rNR^1CONR^{17}R^{18}$; $-(CHR^{15})_rNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_rPO(OR^1)_2$; $-(CHR^{15})_rSO_2R^{17}$; $-(CHR^{15})_rNR^1SO_2R^{17}$; $-(CHR^{15})_rSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or

$-(CHR^1)_rO(CHR^1)_oR^{35}$; or

R^{11} and R^{12} taken together can form

=O; or $=NR^1$;

R^{13} and R^{14} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_rO(CHR^1)_oR^{35}$;

R^{15} is H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^{17}R^{18}$; $-(CHR^1)_oNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; $-(CHR^1)_oSO_2R^{17}$; or $-(CHR^1)_oSO_2NR^{17}R^{18}$;


R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; heteroaryl-heterocycloalkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently

H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; or heteroaryl-heterocycloalkyl; or the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form:

heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl;

or a group of one of the formulae



Z, Z' and Z'' are independently

$-CR^{39}$; or N;

R^{21}, R^{22}, R^{23} and R^{24} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_nO(CHR^2)_mR^{38}$;

R^{25} and R^{26} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_rOR^{17}$; $-(CHR^1)_rSR^{17}$; $-(CHR^1)_rNR^2R^{17}$; $-(CHR^1)_rOCONR^2R^{17}$; $-(CHR^1)_rNR^2CONR^3R^{17}$;$-(CHR^1)_rNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_rPO(OR^2)_2$; $-(CHR^1)_rSO_2R^{17}$; $-(CHR^1)_rNR^2SO_2R^{17}$; $-(CHR^1)_rSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{27} is H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{29} is H; alkyl; alkenyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; $-(CHR^4)_oOR^{17}$; $-(CHR^4)_oSR^{17}$; or $-(CHR^4)_rNR^{17}R^{18}$;

R^{30} is $-(CR^1R^4)_nR^{35}$; $-(CH_2)_nO(CH_2)_mR^{35}$; $-(CH_2)_nS(CH_2)_mR^{35}$; or $-(CH_2)_nNR^1(CH_2)_mR^{35}$;


R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}R^{32}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qOR^{32}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{19}SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^2)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

R^{32} is $-COR^{29}$; $-COR^{30}$; $-CO(CR^1R^{15})_oR^{17}$; $-CO(CR^1R^{15})_oOR^{17}$; $-CO(CR^1R^{15})_oNR^{17}R^{18}$; $-CO(CR^1R^{15})_oNR^2R^{16}$; $-CO(CR^1R^{29})NR^{17}R^{18}$; $-CO(CR^1R^{30})NR^{17}R^{18}$; $-CO(CR^1R^{34})NR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}SO_2R^{18}$; $-CO(CR^1R^{15})_oNR^{17}SO_2R^{18}$; $-CONR^1(CHR^{17})_nNR^2(CHR^{15})_mR^{16}$; $-CO(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-CONR^1(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-SO_2R^{29}$; $-SO_2R^{30}$; $-SO_2(CR^1R^{15})_oR^{17}$; or $-SO_2(CR^1R^{15})_oNR^{17}R^{18}$;


R^{33} is $-NR^1C(R^2)(R^{29})COOR^{17}$; $-NR^1C(R^2)(R^{29})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{30})COOR^{17}$; $-NR^1C(R^2)(R^{30})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{34})COOR^{17}$; or $-NR^1C(R^2)(R^{34})CONR^{17}R^{18}$;

R^{34} is $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CH_2)_qC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^2C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^1R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^1)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; or $-(CR^1R^{15})_qCONR^{17}R^{18}$;


R^{35} is an aryl group of one of the formulae



AR1




AR2




AR3


or a heteroaryl group of one of the formulae




H1




H2




H3




H4




H5




H6




H7




H8




H9




H10




H11




H12




H13





H14





H15



H16



H17



H18



H19



H20



H21



H22



H23



H24



H25



H26



H27



H28



H29



H30



H31



H32



H33



H34



H35



H36



H37



H38



H39



H40


H41



H42


H43



H44




H45




H46




H47




H48



H49



H50




H51

R^{36} and R^{37} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_oR^{38}$; $-(CH_2)_oOR^{17}$; $-O(CH_2)_oR^{38}$; $-(CH_2)_oSR^{17}$; $-(CH_2)_oNR^{17}R^{18}$; $-(CH_2)_oOCONR^{17}R^{18}$; $-(CH_2)_oNR^1CONR^{17}R^{18}$; $-(CH_2)_oNR^1COR^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^{17}R^{18}$; $-(CH_2)_oPO(OR^1)_2$; $-(CH_2)_oSO_2R^{16}$; or $-(CH_2)_oCOR^{17}$;

R^{38} is an aryl group of the formula



AR4

R^{39}, R^{40} and R^{41} are independently

H; F; Cl; Br; OH; NH_2; NO_2; CN; CF_3; $OCHF_2$; OCF_3; $-NR^1R^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^1R^{17}$; lower alkyl; lower alkoxy; or lower alkenyl;


R^{42} is H; lower alkyl; or aryl-lower alkyl;

n and m are independently an integer of 0-5 with the proviso that $n+m \leq 6$;

o is 0-4; p is 2-6; q is 1-6; r is 1-3; s is 0-4;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition related to the activity of CXCR7.

2. A method of treating a disease or condition related to the activity of CXCR7 comprising administering to a subject in need thereof a therapeutically effective amount of a compound of general formula (I)




(I)


wherein the single elements T or P are connected in either direction from the carbonyl (C=O) point of attachment to the nitrogen (N) of the next element and wherein

– either


T^1 is an α-amino acid residue of one of the formulae




AA1




AA2




AA3




AA4




AA5




AA6




AA7



AA8




AA9




AA10

and


T^2 is an α-amino acid residue of one of the formulae




AA11




AA12




AA13




AA14



AA15




AA16




AA17

– or


T^1 is an α-amino acid residue of one of the formulae




AA18




AA19




AA20



AA21




AA22




AA23

and


T^2 is an α-amino acid residue of one of the formulae AA11 to AA17, hereinabove, or ar α-amino acid residue of one of the formulae




AA24




AA25




AA26




AA27




AA28




AA29



AA30



AA31




AA32

P^1, P^3 and P^4 are independently

$-NR^1CH(R^{29})CO-$; $-NR^1CH(R^{30})CO-$; or $-NR^1CH(R^{31})CO-$;

P^2 is an α-amino acid residue of one of the formulae



AA33 AA34

A is O; NR^{17}; S; SO; or SO_2;

X is OH; NH_2; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

Y is NH_2; F; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

R^1, R^2 and R^3 are independently

H; CF_3; lower alkyl; lower alkenyl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R^4, R^5, R^6, R^7 and R^8 are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_nO(CHR^2)_mR^{35}$; or

R^4 and R^2 taken together can form

=O; $-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5; R^5 and R^6; R^6 and R^7; R^7 and R^8; or R^6 and R^9 taken together can form:

$-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5 are independently X;

R^9, R^{10}, R^{11} and R^{12} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_rOR^{17}$; $-(CHR^{15})_rSR^{17}$; $-(CHR^{15})_rNR^{17}R^{18}$; $-(CHR^{15})_rOCONR^{17}R^{18}$; $-(CHR^{15})_rNR^1CONR^{17}R^{18}$; $-(CHR^{15})_rNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_rPO(OR^1)_2$; $-(CHR^{15})_rSO_2R^{17}$; $-(CHR^{15})_rNR^1SO_2R^{17}$; $-(CHR^{15})_rSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or

$-(CHR^1)_rO(CHR^1)_oR^{35}$; or

R^{11} and R^{12} taken together can form

=O; or $=NR^1$;

R^{13} and R^{14} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_rO(CHR^1)_oR^{35}$;

R^{15} is H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^{17}R^{18}$; $-(CHR^1)_oNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; $-(CHR^1)_oSO_2R^{17}$; or $-(CHR^1)_oSO_2NR^{17}R^{18}$;


R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; heteroaryl-heterocycloalkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently


H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; or heteroaryl-heterocycloalkyl; or the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form:

heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl;


or a group of one of the formulae




C1




C2




C3




C4




C5



C6



C7



C8

Z, Z' and Z'' are independently

-CR^{39}; or N;

R^{21}, R^{22}, R^{23} and R^{24} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -$(CHR^1)_oOR^{17}$; -$(CHR^1)_oSR^{17}$; -$(CHR^1)_oNR^2R^{17}$; -$(CHR^1)_oOCONR^2R^{17}$; -$(CHR^1)_oNR^2CONR^3R^{17}$; -$(CHR^1)_oNR^2COR^{17}$; -$(CHR^1)_oCOOR^{17}$; -$(CHR^1)_oCONR^2R^{17}$; -$(CHR^1)_oPO(OR^2)_2$; -$(CHR^1)_oSO_2R^{17}$; -$(CHR^1)_oNR^2SO_2R^{17}$; -$(CHR^1)_oSO_2NR^2R^{17}$; -$(CR^1R^2)_oR^{38}$; or -$(CHR^1)_nO(CHR^2)_mR^{38}$;

R^{25} and R^{26} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -$(CHR^1)_rOR^{17}$; -$(CHR^1)_rSR^{17}$; -$(CHR^1)_rNR^2R^{17}$; -$(CHR^1)_rOCONR^2R^{17}$; -$(CHR^1)_rNR^2CONR^3R^{17}$;-$(CHR^1)_rNR^2COR^{17}$; -$(CHR^1)_oCOOR^{17}$; -$(CHR^1)_oCONR^2R^{17}$; -$(CHR^1)_rPO(OR^2)_2$; -$(CHR^1)_rSO_2R^{17}$; -$(CHR^1)_rNR^2SO_2R^{17}$; -$(CHR^1)_rSO_2NR^2R^{17}$; -$(CR^1R^2)_oR^{38}$; or -$(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{27} is H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{29} is H; alkyl; alkenyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; $-(CHR^4)_oOR^{17}$; $-(CHR^4)_oSR^{17}$; or $-(CHR^4)_rNR^{17}R^{18}$;

R^{30} is $-(CR^1R^4)_nR^{35}$; $-(CH_2)_nO(CH_2)_mR^{35}$; $-(CH_2)_nS(CH_2)_mR^{35}$; or $-(CH_2)_nNR^1(CH_2)_mR^{35}$;


R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}R^{32}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qOR^{32}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{19}SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^2)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

R^{32} is $-COR^{29}$; $-COR^{30}$; $-CO(CR^1R^{15})_oR^{17}$; $-CO(CR^1R^{15})_oOR^{17}$; $-CO(CR^1R^{15})_oNR^{17}R^{18}$; $-CO(CR^1R^{15})_oNR^2R^{16}$; $-CO(CR^1R^{29})NR^{17}R^{18}$; $-CO(CR^1R^{30})NR^{17}R^{18}$; $-CO(CR^1R^{34})NR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}SO_2R^{18}$; $-CO(CR^1R^{15})_oNR^{17}SO_2R^{18}$; $-CONR^1(CHR^{17})_nNR^2(CHR^{15})_mR^{16}$; $-CO(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-CONR^1(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-SO_2R^{29}$; $-SO_2R^{30}$; $-SO_2(CR^1R^{15})_oR^{17}$; or $-SO_2(CR^1R^{15})_oNR^{17}R^{18}$;


R^{33} is $-NR^1C(R^2)(R^{29})COOR^{17}$; $-NR^1C(R^2)(R^{29})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{30})COOR^{17}$; $-NR^1C(R^2)(R^{30})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{34})COOR^{17}$; or $-NR^1C(R^2)(R^{34})CONR^{17}R^{18}$;

R^{34} is $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CH_2)_qC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$;
$-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^2C(=NR^{19})NR^{17}R^{18}$;
$-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$;
$-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^1R^{16}$;
$-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^1)_2$;
$-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$;
$-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$;
$-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$;
$-(CR^1R^{15})_qCOOR^{17}$; or $-(CR^1R^{15})_qCONR^{17}R^{18}$;


R^{35} is an aryl group of one of the formulae



AR1




AR2




AR3


or a heteroaryl group of one of the formulae




H1




H2




H3




H4




H5




H6




H7




H8




H9




H10




H11




H12




H13





H14





H15



H16



H17



H18



H19



H20



H21



H22



H23



H24



H25



H26



H27



H28



H29



H30



H31



H32



H33



H34



H35



H36



H37



H38



H39



H40


H41



H42


H43



H44




H45




H46




H47




H48



H49



H50




H51

R^{36} and R^{37} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_oR^{38}$; $-(CH_2)_oOR^{17}$; $-O(CH_2)_oR^{38}$; $-(CH_2)_oSR^{17}$; $-(CH_2)_oNR^{17}R^{18}$; $-(CH_2)_oOCONR^{17}R^{18}$; $-(CH_2)_oNR^1CONR^{17}R^{18}$; $-(CH_2)_oNR^1COR^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^{17}R^{18}$; $-(CH_2)_oPO(OR^1)_2$; $-(CH_2)_oSO_2R^{16}$; or $-(CH_2)_oCOR^{17}$;

R^{38} is an aryl group of the formula



AR4

R^{39}, R^{40} and R^{41} are independently

H; F; Cl; Br; OH; NH_2; NO_2; CN; CF_3; $OCHF_2$; OCF_3; $-NR^1R^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^1R^{17}$; lower alkyl; lower alkoxy; or lower alkenyl;

R^{42} is H; lower alkyl; or aryl-lower alkyl;

n and m are independently an integer of 0-5 with the proviso that $n+m \leq 6$;

o is 0-4; p is 2-6; q is 1-6; r is 1-3; s is 0-4;

or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1 or the method according to claim 2, wherein

R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form: heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl; or a group of one of the above formulae C1 to C8;

R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

s is 2-4.

4. The use according to claim 1 or the method according to claim 2, wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1, P^3 and P^4 are independently

Ala; Arg; Asn; Asp; Cit; Cys; Glu; Gln; Gly; His; Ile; Leu; Lys; Met; Orn; Phe; Pro; Ser; Thr; Trp; Tyr; Val; Abu; Agb; Agp; Ala(*t*Bu); Ala(*c*Pr); Ala(2Furyl); Ala(3Furyl); Ala(Ppz); Ala(1Pyraz); Ala(2Quin); Ala(3Quin); Ala(4Quin); Ala(Tet); Azt; Bbta; Bip; Cha; Chg; Dab; Dab(Ac); Dab(*c*Pr); Dab(*i*Pr); Dab($4Me_2NPhSO_2$); Dab(MeOEtNCO); Dab(MePpzCO); Dab($MeSO_2$); Dab(morphCO); Dab(1Nal); Dab(2Nal); Dap; Dap($CONH_2$); Dap(MeOEt); Dap($(MeOEt)_2$); Deg; Gly(*t*Bu); hArg; hCha; hCys; hHis; hLys; hPhe; hSer; hSer(Me); hTrp; hTyr; His(Me); His(Bn); Hyp(Bn); (4*S*)-Hyp(Bn); Hyp(4BrBn); Hyp(3CNBn); Hyp(4CNBn); Hyp(CONHPh); Hyp(Ph); Lys(Ac); Lys(Bz); Lys(*c*Pr); Lys(*i*Pr); Lys(Me); Lys(Nic); Lys((5*R*)OH); Lys(4Oxa); Met(O_2); 1Nal; 2Nal; Nle; Nle(6OBn); OctG; Oic; Orn(*c*Pr); Orn(*i*Pr); 2Pal; 3Pal; 4Pal; Phe(2Cl); Phe(3Cl); Phe(4Cl); Phe($3,4Cl_2$); Phe(2F); Phe(3F); Phe(4F); Phe(4CN); Phe($4CF_3$); Phe(4COOMe); Phg; Pip; Pro((4*R*)Bn); Pro((4*S*)F); Pro((4*S*)*c*Hex); Pro($5,5Me_2$); Ser(Bn); Ser(Me); Thi; *allo*Thr; Thr(Bn); Thz; Thz($5,5Me_2$); Tic; Tic(7OH); Trp(7Aza); Trp(5Br); Trp(6Br); Trp($6CF_3$); Trp(5Cl); Trp(6Cl); Trp(5,6Cl); Trp(5OH); Tyr(Bn); Tyr(Me); Tyr(4MeOCOBn); Tyr(Ph); Tyr(4OHPh); Tza; Gln(Alk1); Gln(Alk2); Gln(Alk3); Gln(Alk4); Gln(Alk5); Gln(Alk6); Gln(Alk7); Gln(Alk8); Gln(Alk9); Gln(Alk10); Gln(Alk11); Gln(Alk12); Gln(Alk13); Gln(Alk14); Gln(Alk15); Gln(Alk16); Gln(Alk17); Gln(Alk18); Gln(Alk19); Gln(Alk20); Gln(Alk21); Gln(Alk22); Gln(Alk23); Gln(Alk24); Gln(Alk25); Gln(Alk26); Gln(Alk27); Gln(Alk28); Gln(Alk29); Gln(Alk30); Gln(Alk31); Gln(Alk32); Gln(Alk33); Gln(Alk34); Glu(cN1); Glu(cN2); Glu(cN3); Glu(cN4); Glu(cN5); Glu(cN6); Glu(cN7); Glu(cN8); Glu(cN9); Glu(cN10); Glu(cN11); Glu(cN12); Glu(cN13); Glu(cN14); Glu(cN15); Glu(cN16); Glu(cN17); Lys(Ar1); Lys(Ar2); Lys(Ar3); Lys(Ar4); Lys(Ar5); Lys(Ar6); Lys(Ar7); Lys(Ar8); Lys(Ar9); Lys(Ar10); Lys(Ar11); Lys(Ar12); Orn(Ar1); Orn(Ar2); Orn(Ar3); Orn(Ar4); Orn(Ar5); Orn(Ar6); Orn(Ar7); Orn(Ar8); Orn(Ar9); Orn(Ar10); Orn(Ar11);

Orn(Ar12); Dab(Ar1); Dab(Ar2); Dab(Ar3); Dab(Ar4); Dab(Ar5); Dab(Ar6); Dab(Ar7); Dab(Ar8); Dab(Ar9); Dab(Ar10); Dab(Ar11); Dab(Ar12); Dab(S1); Dab(S2); Dab(S3); Dab(S4); Dab(S5); Dab(S6); Dab(S7); Dab(S8); Dab(S9); Dab(S10); Dab(S11); Dab(S12); Dab(S13); Dab(S14); Dab(S15); Dab(S16); Dab(S17); Dab(S18); Dab(A1); Dab(A2); Dab(A3); Dab(A4); Dab(A5); Dab(A6); Dab(A7); Dab(A8); Dab(A9); Dab(A10); Dab(A11); Dab(A12); Dab(A13); Dab(A14); Dab(A15); Dab(A16); Dab(A17); Dab(A18); Dab(A19); Dab(A20); Dab(A21); Dab(A22); Dab(A23); Dab(A24); Dab(A25); Dab(A26); Dab(A27); Dab(A28); Dab(A29); Dab(A30); Dab(A31); Dab(A32); Dab(A33); Dab(A34); Dab(A35); Dab(A36); Dab(A37); Dab(A38); Dab(A39); Dab(A40); Dab(A41); Dab(A42); Dab(A43); Dab(A44); Dab(A45); Dab(A46); Dab(A47); Dab(A48); Dab(A49); Dab(A50); Dab(A51); Dab(A52); Dab(A53); Dab(A54); Dab(A55); Orn(A1); Orn(A2); Orn(A3); Orn(A4); Orn(A5); Orn(A6); Orn(A7); Orn(A8); Orn(A9); Orn(A10); Orn(A11); Orn(A12); Orn(A13); Orn(A14); Orn(A15); Orn(A16); Orn(A17); Orn(A18); Orn(A19); Orn(A20); Orn(A21); Orn(A22); Orn(A23); Orn(A24); Orn(A25); Orn(A26); Orn(A27); Orn(A28); Orn(A29); Orn(A30); Orn(A31); Orn(A32); Orn(A33); Orn(A34); Orn(A35); Orn(A36); Orn(A37); Orn(A38); Orn(A39); Orn(A40); Orn(A41); Orn(A42); Orn(A43); Orn(A44); Orn(A45); Orn(A46); Orn(A47); Orn(A48); Orn(A49); Orn(A50); Orn(A51); Orn(A52); Orn(A53); Orn(A54); Orn(A55); Orn(A56); Asn(Alk1); Asn(Alk2); Asn(Alk3); Asn(Alk4); Asn(Alk5); Asn(Alk6); Asn(Alk7); Asn(Alk8); Asn(Alk9); Asn(Alk10); Asn(Alk11); Asn(Alk12); Asn(Alk13); Asn(Alk14); Asn(Alk15); Asn(Alk16); Asn(Alk17); Asn(Alk18); Asn(Alk19); Asn(Alk20); Asn(Alk21); Asn(Alk22); Asn(Alk23); Asn(Alk24); Asn(Alk25); Asn(Alk26); Asn(Alk27); Asn(Alk28); Asn(Alk29); Asn(Alk30); Asn(Alk31); Asn(Alk32); Asn(Alk33); Asn(Alk34); Asp(cN1); Asp(cN2); Asp(cN3); Asp(cN4); Asp(cN5); Asp(cN6); Asp(cN7); Asp(cN8); Asp(cN9); Asp(cN10); Asp(cN11); Asp(cN12); Asp(cN13); Asp(cN14); Asp(cN15); Asp(cN16); Asp(cN17); Dap(Ar1); Dap(Ar2); Dap(Ar3); Dap(Ar4); Dap(Ar5); Dap(Ar6); Dap(Ar7); Dap(Ar8); Dap(Ar9); Dap(Ar10); Dap(Ar11); Dap(Ar12); Dap(S1); Dap(S2); Dap(S3); Dap(S4); Dap(S5);

Dap(S6); Dap(S7); Dap(S8); Dap(S9); Dap(S10); Dap(S11); Dap(S12); Dap(S13); Dap(S14); Dap(S15); Dap(S16); Dap(S17); Dap(S18); Dap(A1); Dap(A2); Dap(A3); Dap(A4); Dap(A5); Dap(A6); Dap(A7); Dap(A8); Dap(A9); Dap(A10); Dap(A11); Dap(A12); Dap(A13); Dap(A14); Dap(A15); Dap(A16); Dap(A17); Dap(A18); Dap(A19); Dap(A20); Dap(A21); Dap(A22); Dap(A23); Dap(A24); Dap(A25); Dap(A26); Dap(A27); Dap(A28); Dap(A29); Dap(A30); Dap(A31); Dap(A32); Dap(A33); Dap(A34); Dap(A35); Dap(A36); Dap(A37); Dap(A38); Dap(A39); Dap(A40); Dap(A41); Dap(A42); Dap(A43); Dap(A44); Dap(A45); Dap(A46); Dap(A47); Dap(A48); Dap(A49); Dap(A50); Dap(A51); Dap(A52); Dap(A53); Dap(A54); or Dap(A55);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dab; ^{D}Phe; ^{D}Phe(4CF_3); ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; ^{D}4Pal; ^{D}Lys(Ar1); ^{D}Lys(Ar2); ^{D}Lys(Ar3); ^{D}Lys(Ar4); ^{D}Lys(Ar5); ^{D}Lys(Ar6); ^{D}Lys(Ar7); ^{D}Lys(Ar8); ^{D}Lys(Ar9); ^{D}Lys(Ar10); ^{D}Lys(Ar11); ^{D}Lys(Ar12); ^{D}Orn(A41); ^{D}Orn(A56); ^{D}Orn(Ar1); ^{D}Orn(Ar2); ^{D}Orn(Ar3); ^{D}Orn(Ar4); ^{D}Orn(Ar5); ^{D}Orn(Ar6); ^{D}Orn(Ar7); ^{D}Orn(Ar8); ^{D}Orn(Ar9); ^{D}Orn(Ar10); ^{D}Orn(Ar11); ^{D}Orn(Ar12); ^{D}Dab(Ar1); ^{D}Dab(Ar2); ^{D}Dab(Ar3); ^{D}Dab(Ar4); ^{D}Dab(Ar5); ^{D}Dab(Ar6); ^{D}Dab(Ar7); ^{D}Dab(Ar8); ^{D}Dab(Ar9); ^{D}Dab(Ar10); ^{D}Dab(Ar11); ^{D}Dab(Ar12); ^{D}Dap(Ar1); ^{D}Dap(Ar2); ^{D}Dap(Ar3); ^{D}Dap(Ar4); ^{D}Dap(Ar5); ^{D}Dap(Ar6); ^{D}Dap(Ar7); ^{D}Dap(Ar8); ^{D}Dap(Ar9); ^{D}Dap(Ar10); ^{D}Dap(Ar11); or ^{D}Dap(Ar12).

5. The use according to claim 1 or the method according to claim 2, wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Ala(*c*Pr); Ala(1Pyraz); Ala(Tet); Trp; 1Nal; 2Nal; Phe; Tyr; 2Pal; 3Pal; 4Pal; Thr; His; Arg; hArg; Agb; Pip; Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dap; ^{D}Phe; ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; or ^{D}4Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Cit; Thr; Dab; Dap; Phe; Trp; His; Tyr; or Ile

P^4 is Trp; His; Phe; Phe($4CF_3$); 1Nal; 2Nal; Tyr; Leu; Ile; Arg; hArg; Lys; Dab; Dap; Orn; Orn(A56); or Orn(Ar7).

6. The use according to claim 1 or the method according to claim 2, wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); or ^{D}Pro((4*S*)NH_2);

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*S*)OH); (4*S*)-Hyp(Bn); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Trp; 1Nal; Tyr; 3Pal; Thr; His; Arg; hArg; Agb; Pip; Ala(1Pyraz); Ala(Tet); Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Phe; ^{D}Trp; ^{D}His; or ^{D}3Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Dab; Trp; or His;

P^4 is Trp; His; Phe; Phe($4CF_3$); 1Nal; 2Nal; Tyr; Ile; Arg; hArg; Lys; Dab; Orn; Orn(A56); or Orn(Ar7).

7. The use according to claim 1 or the method according to claim 2, wherein the compound of formula (I) is selected from

cyclo(-Ile-^{D}Arg-Arg-Ile-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Tyr-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Lys-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Dab-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Dab-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Thr-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-hSer-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-*allo*Thr-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Lys-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}His-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Cit-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-1Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Thr-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Ile-^{D}Arg-Agp-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Agb-Trp-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Tyr-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Lys-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-His-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Pip-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-hArg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Agb-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}3Pal-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-hArg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)F)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*R*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Mor-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Mor-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-(4*S*)-Hyp(Bn)-);

cyclo(-His-^{D}Trp-His-Trp-^{D}Pro- Pro((4*S*)NHBz)-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*S*)OH)-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*R*)NH_2)-Thr-);

cyclo(-Val-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Abu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Leu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Nle-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Cha-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Orn-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A41)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Tic-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(A56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

8. The use or method according to claim 7, wherein the compound of formula (I) is selected from

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

and pharmaceutically acceptable salts thereof.

9. The use or method according to claim 7, wherein the compound of formula (I) is selected from

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

10. The use according to any one of claims 1, or 3 to 9, or the method according to any one of claims 2 to 9, wherein the compound of formula (I) is an epimer or a diastereomer based on one or more chiral centers not expliccitly specified in formula (I).

11. The use of a compound of formula (I) as defined in any one of claims 1 to 10 in the manufacture of a medicament for the treatment of a disease or condition treatable by modulating activity against the CXCR7 receptor.

12. A method of treating a disease or condition treatable by modulating activity against the CXCR7 receptor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) as defined in any one of claims 1 to 10.

13. The use according to claim 11 or the method according to claim 12, wherein the disease or condition is treatable by interfering selectively with the natural activity of the CXCR7 receptor and its natural ligands CXCL11 and/or CXCL12.

14. The use of a compound of formula (I) as defined in any one of claims 1 to 10 in the manufacture of a medicament for the treatment, prevention or the supportive treatment of a disease or condition related to the activity of CXCR7 selected from dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and oncology, or the mobilisation of stem cells.

15. A method for the treatment, prevention or the supportive treatment of a disease or condition related to the activity of CXCR7 selected from dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and oncology, or the mobilisation of stem cells comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) as defined in any one of claims 1 to 10.

16. The use according to claim 14 or the method accordign to claim 15, wherein the disease or condition related to the activity of CXCR7 is selected from HIV infections, Epstein-Barr Virus infection; Type I andor Type II diabetes mellitus; conjunctivitis, scleritis, uveitis, rhinosinusitis, Whim syndrome, lupus erythematosus, osteoarthritis, rheumatoid arthritis, synovitis, psoriasis, multiple sclerosis, Crohns disease, inflammatory bowl disease, mixed connective tissue disease, chronic lymphocytic thyroiditis, Graves' disease, graft-versus-host disease, Sjögren's syndrome; dry eye syndrome, glaucoma, age-related macular

degeneration; pulmonary arterial hypertension, pulmonary hypoxia, atherosclerosis, myocarditis, heart failure including myocardial infarction, arterial thrombosis, strike and angiogenesis; chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma; sarcomaincluding asteosarcoma, rhabdomyosarcoma, Kaposi's sarcoma and synoovial sarcoma; lipoma including angiolipoma; glioblastoma multiforme, astrocytomas, neuroblastoma; carcinoma including adenocarcinoma; malignant epithelial and mucoepidermoid neoplasms, thyroid neoplasm, gonadal neoplasms, prostate cancer, breast cancer, melanoma, lung carcinoma, pancreatic carcinoma, colorectal cancer; solid tumors; lymphoma including Birkitt's lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma; multiple myeloma and leukemia; and metastasis.

17. Use of a compound of formula (I) as defined in any one of claims 1 to 10, in the manufacture of a medicament for the inhibition of neointima formation; stem cell mobilisation of peripheral blood stem cells and/or mesenchymal stem cells; mobilisation of endothelial or neuronal progenitor cells; or tissue-repair in human or other mammals.

18. A method of inhibiting neointima formation; mobilising peripheral blood stem cells and/or mesenchymal stem cells, endothelial or neuronal progenitor cells; or tissue repair, in a human or other mammal, comprising administering an effective amount of a compound of formula (I) as defined in any one of claims 1 to 10, to a subject in need thereof.

19. The use according to any one of claims 1 or 3 to 11, 13, 14, 16 or 17, or the method according to any one of claims 2 to 10, 12, 13, 15, 16 or 18, wherein the medicament is in a form suitable for, or the administration is, oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation administration.

20. The use according to claim 19, wherein the medicament is in the form of a tablet, a dragee, a capsule, a solution, a liquid, a gel, a plaster, a cream, an ointment, a syrup, a slurry, a suspension, a spray, a nebuliser or a suppository.

21. The use according to any one of claims 1, or 3 to 11, 13, 14, 16 or 17, wherein the medicament is adapted to administer the compound of formula (I) as the sole active pharmaceutical ingredient or in combination with one or more other active pharmaceutical ingredients present in the medicament or in another medicament.